Application form

Beazley | Life Sciences



Beazley Life Sciences Form

NOTICE: PART OR ALL OF THE POLICY FOR WHICH THIS APPLICATION IS MADE IS WRITTEN ON A CLAIMS MADE BASIS, WHICH MEANS THAT THE POLICY APPLIES ONLY TO ANY CLAIM FIRST MADE AGAINST THE INSURED DURING THE POLICY PERIOD OR THE OPTIONAL EXTENDED REPORTING PERIOD, IF APPLICABLE. AMOUNTS INCURRED AS CLAIMS EXPENSES SHALL REDUCE AND MAY EXHAUST THE LIMIT OF LIABILITY AND ARE SUBJECT TO THE DEDUCTIBLE. PLEASE READ THE POLICY CAREFULLY. ANSWER ALL QUESTIONS COMPLETELY. UNANSWERED QUESTIONS WILL BE INTERPRETED AS HAVING BEEN MARKED "NOT APPLICABLE" BY APPLICANT. IF ADDITIONAL SPACE IS NEEDED TO ANSWER ANY QUESTION FULLY, PLEASE ATTACH A SEPARATE PAGE. THIS APPLICATION WILL BE ATTACHED TO AND MADE PART OF ANY POLICY ISSUED.

Please provide the following information:

- 1. Detailed Loss History for the last FIVE years. The loss runs should be updated within the last 30 days, and include a breakdown of total incurred losses (paid and reserves for both indemnity and expense), and a description of all losses, whether paid or outstanding.
- 2. Most recent AUDITED financial statements.
- 3. Copy of CONTRACTUAL AGREEMENT(S) in place with whom you enter into a service for a fee agreement.
- 4. Copy of Human Clinical Trial PROTOCOL(S) and INFORMED CONSENT FORM(S)
- 5. Copy of recently issued WARNING LETTERS/and RESPONSES
- 6. Most recent local and/or provincial/territorial accreditation agency reports.
- 7. Any marketing brochures or literature detailing services provided.

Section 1 – Applicant/Broker Information

1.	First named insured:				
2.	Address (street, city, state, postal cod	e):			
3.	Website address:				
4.	Mailing address (if different from abo	ve):			
5.	Company years in business:	(mm/dd/yyyy)	/	/	
6.	Contact (name, phone number, email):			



BZSL048-CA-0220 Last Updated: 09/2020

7.	Broker firm (street, city, state, postal code):						
8.	Broker contact (name, phone number, email):						
9.	Type of entity:						
	a. Corporation	b. f.	Partnership Limited Liability Company	c. Non-profit	d.	Individual	
10.	Parent company (name and addre	ress	5):				
11.	Additional insureds (please list):						
	a.						
	b.						
	C.						
12.	Additional named insureds (owne	ersh	nip % must be >50%):				
	a.						
	b.						
40	C.	43					
13.	Brief description of company oper	erati	OUS:				

beazley

14.	Has the company filed for bankruptcy in the last 7 years?	Yes	No	N/A
15.	Has the company had any mergers/acquisitions in the last 6 years and/or have any plans in the next 12 months?	Yes	No	N/A
16.	Is the company/shareholders/directors/officers/partners/members thereof under any investigation for alleged criminal violations relating to business?	Yes	No	N/A
17.	Has the company ever operated under a different name?	Yes	No	N/A
	If answered 'Ves' to any questions 15 - 17, please explain here:			

Section 2 – Coverage Information

18. Coverage effective dates: From: (mm/dd/yyyy) / / To: (mm/dd/yyyy) / /

19. Prior insurance history: Check here if no prior coverage: New

Year	Coverage	Carrier	Limits	Deductible	Premium



20. Policy limits/Deductible/Retroactive dates request

	Limits	Deductible	Retroactive date
Errors and omissions liability			
Healthcare professional services			
Products/completed operations liability			
General liability			
Clinical trial medical expenses			
Clinical trials medical monitoring expenses			
Products medical expenses			
Products medical monitoring expenses			

21. Revenue History

	Canada	U.S.	Rest of World	Total
Projected				
Last year				
1st Prior				
2nd Prior				
3rd Prior				

22. Please provide a breakdown of revenue by product/service for the current financial year as follows:

Please provide a full listing of Services and/or Products offered, and the percentage of Total Gross Revenue. The total must equal 100%.

If these are Human Clinical Trials, check box and complete the Clinical Trials section in the application.

Pharmaceuticals/ Biologics/Nutra	%	Medical Devices	%	Contracted Professionals	%
Injectable/Oral prescription		Analytical instruments		Contract research organization	
Benzodiazepine		Surgical instruments		Contract manufacturer	
SSRI's or SNRI's		Dental instruments		Academic medical institution	
Cannabinoids		Diagnostic kits		Site management organization	
Scheduled I or II Substance		Hospital Products/Supplies		Lab services	
Opioids		Mobility aides		Clinical staff recruitment/Training	
Fertility/Birth control		Monitoring devices		Database management/ Regulatory filings/Medical writing	
Hormone replacement		Imaging devices		Distribution	
Drug delivery/ Nanoparticles		Anesthesia/Respiratory		Assembly/Repackaging	
Generic Pharma		Pain pumps		Quality assurance/Control	
Imaging/Diagnostic agents		Implantable-Active		Sales/Marketing	
Nutri-parmaceuticals		Metal-on-Metal implants		Sterilisation	
Weight management		Breast implants			
Sexual enhancement		Impantable-Non active			
Topical prescription		Lasers			
Vaccines		Morcellators			
Food supplements/ vitamins		Dialysis			
Cosmetics		Surgical mesh			
		IVC Filters			
		Cold therapy			
		IUD devices			
Other (specify)		Other (specify)		Other (specify)	
Total %	100%	Total %	100%	Total %	100%



Section 3 – Products Completed Operations

23. Please list your Company's products and indicate whether you are the manufacturer or distributor. If you are the manufacturer, please indicate whether you manufacture the entire product or only a part of it. For distributed products, please indicate the product's country of origin.

Product	% of Total Revenue	Manufacturer or Distributor	Whole or Part	Country of origin (for distribution only)

(Attach list if necessary)

24. Please provide a breakdown of your revenues by class of device (as defined by Health Canada, the FDA in the U.S., or any other regulatory authority).

	Last Twelve (12) Months			Next Twelve (12) Months		
	Canada	U.S.	Other	Canada	U.S.	Other
Class 1:						
Class 2:						
Class 3:						
Class 4:						
Other:						
Total:						

25.	Are products or parts manufactured outside Canada?	Yes	No	N/A
	If 'Yes', what product(s) and where?			

26.	Are	you aware of product(s) sold off-label?	Yes	No	N/A
	a.	If so, are off-label products tracked?	Yes	No	N/A
	b.	Do you have procedures in place for inhibiting employees from off label promotions?	Yes	No	N/A



27.	Are any products repackaged or relabeled? If 'Yes', what product(s)?	Yes	No	N/A
28.	Do product(s) have a Black Box or other significant safety warning label(s)? If 'Yes', what product(s)?	Yes	No	N/A
29.	Are product(s) sold as components of other products? If 'Yes', please explain:	Yes	No	N/A
30.	Have product(s) ever been associated with death/permanent injury or hospitalization? If 'Yes', please explain:	Yes	No	N/A
31.	Has any product(s) been recalled in the past 5 years? a. Are you considering recalling any known or suspected defective products from the market? If 'Yes', please explain:	Yes Yes	No No	N/A N/A
32.	Are any products specifically approved for, and used by: minors, pregnant women, cognitively impaired and/or prisoners? If 'Yes', what product(s):	Yes	No	N/A
33.	Have you discontinued any products or services in the last 5 years? a. Are you considering discontinuing any product or service? If 'Yes', please explain:	Yes Yes	No No	N/A N/A



34.	Is applicant considering introducing any new products or services in the next 12 month? If 'Yes', please explain:	Yes	No	N/A
35.	Do you rent/lease medical equipment? If so, what type:	Yes	No	N/A
36.	Do you repair/install/or service medical equipment?	Yes	No	N/A
	If so, are you or your employees factory trained?	Yes	No	N/A
37.	Do you comply with the Health Canada's Good Manufacturing Practices (GMP) or equivalent manufacturing standards for your product(s)?	Yes	No	N/A
38.	Do you maintain the following records:			
	a. When and where product was manufactured?	Yes	No	N/A
	b. To whom the product was sold and date of sale?	Yes	No	N/A
	c. Who supplied the materials for the product?	Yes	No	N/A
	d. Change in design/change in advertising?	Yes	No	N/A
39.	Do any of your products contain the following (including any derivative thereof):	Yes	No	N/A

Aconite, Higenamine; Aegeline; Androstenedione; animal derived products, AMP Citrate, 1,3-dimethylbutylamine citrate.1.3-dimethylbutylamine HCL, methylpentanamine; Aristolochic Acid, BMPEA, B-Methylphenethylamine, Acacia rigidula; Butanediol, Chaparral, Comfrey (Pyrrolizidine alkaloids), Contraceptives or any other products intended to inhibit pregnancy or act as birth control; Chomper, Creatine, Dehydroepiandrosterone, Dendrobium; Dieter's Tea, Dienestrol, diethylstilbestrol, or DES, or which has the same chemical formulary, or which is a stilbene derivative, or any other product or substance having substantially similar formation, structure, or function by whatever name manufactured or marketed as DES; Diethylistbestrol, DMAA, 1,3-dimethylamylamine, dimethylamylamine, methylhexanamine: Ephedra, Ma huang, Ephedra sinica, Chinese Ephedra, ephedrine, ephedrine Alkaloids, pseudoephrine, norpseudoephredine, or any other product or substance having substantially similar formation, structure or function, by whatever name manufactured, grown or marketed; Ephedrine, Estazolam, Gamma Butyrolactone, Gamma Hydroxybutyric Acid, Germander, Germanium, Injectables and implants intended for cosmetic purposes, including but not limited to breast implants, bovine collagen based dermal fillers or implants, human collagen based dermal fillers or implants, hyaluronic acid based dermal fillers or implants, autologous fat transfer, cadaveric based products, and botulinum toxin injections: Isotretinoin, Accutane: Indinavire, Jin Bu huan: Kaya, kaya-kaya and related derivatives; Lobelia; L-Tryptophan or products of any kind or nature which contain L-Tryptophan or any derivative thereof, regardless of whether the product is designated as L-Tryptophan or given any other appellation; Melatonin, oral contraceptives, Pennyroyal Oil; Phenolphthalein or NeoPrunex, or any derivative thereof; Phentermine, Phenylalanine, Phenylpropanolamine, Phenylpropanolamine Hydrochloride, PPA or any product or drug containing any of these substances; Picamilon, N-nicotinoyl-GABA, pycamilon, pikamilon; products that are know mutagens, products that are known teratogens, psychotropic products, SSRI (Selective Serotonin Reuptake Inhibitor) or SNRI (Selective Norepinephrine Reuptake Inhibitor); Stephania; St. John's Wort, Stephania or Magnolia, tobacco or any tobacco products (or ingredients of, or used in the manufacture or production of, such products); Thalidomide; Thimerosal,



Tiractricol, Trix Metabolic Accelerator, Vaccines, toxoids, sera and other immunizing agents; Vinpocetine, Cavinton, Intelectol, ethyl apovincaminate; weight reduction products, Willow Bark, and Yohimbe?

arising out of any product used for the treatment of obesity, weight loss and/or weight management, including but not limited to suppressants containing fenfluramine (Ponderal, Ponderal Pacaps, Pondimin) or dexfenfluramine (Redux) or as part of a combined therapy known as fenphen (fenfluramine and phentermine);

any product containing silicone or similar which is in any form implanted or injected in the body;

If 'YES', please explain.

Section 4 – Human Clinical Trials

40. Test subjects enrollment history:

	Canada participants	U.S. participants	Rest of World participants	Number of minor participants	Total
Projected					
Last year					
Prior					

41. Schedule of human clinical trial(s):

Please provide copy of Protocol and Informed Consent Form for each sponsored trial (use attachment if necessary)

Product/Protocol Name & Number	Number of Test Subjects encolled last year	Number of Test Subjects Newly Enrolled this Year	Phase of Trial and Indication/ Disease tested	Country of Trials	Ongoing/ Completed

42.	Hum	nan clinical trial	s supplement	al questions:				
	a.	Are all of your by an Institution If 'No', please	onal Review B	approved and sub oard?	eject to oversight	Yes	No	N/A
	b.	Do you operat	e an in-patien	t facility?		Yes	No	N/A
		If so, how mar	ny beds?					
	C.	Do you or your		ver act as both th	e Trial Sponsor and Clinical Investigato	r? Yes	No	N/A
	d.	Do your emplo	oyees participa	ate on an Institution	onal Review Board?	Yes	No	N/A
	e.	Has any of you If so, please e		suspended/place	on hold because of safety concerns?	Yes	No	N/A
	f.	Are any of the	following ince	ntives provided to	the Clinical Investigator:	Yes	No	N/A
		Money	Stock	Position	Other			
	g.	Have any clinion in connection	_		regulatory violations	Yes	No	N/A
		If 'Yes', please	e explain:					
	h.	In the past 12		there been any A	ER's or SAER's filed?	Yes	No	N/A
	i.	-	_	en issued against	: you or your Investigators?	Yes	No	N/A
		If 'Yes', please	e explain:					



j.	Have there been any clinical trial "For Cause Audits" conducted in the last 5 years?	Yes	No	N/A
	If so, please explain:			
L	De any aliminal trials invalve minera (vadenthe area of 4000		N.I.	B.I. / A
k.	Do any clinical trials involve minors (under the age of 18)?	Yes	No	N/A
l.	Are any subjects approved for expanded access/compassionate use?	Yes	No	N/A
	If so, how many			
m.	Do you publish all clinical trial results?	Yes	No	N/A
n.	Do you ever provide material/product for another organization's clinical trial? If so, please explain:	Yes	No	N/A

Section 5 – Healthcare Professional Services

43. Healthcare Professional Staff:

Name	Specialty	Board certification	Hours worked	Full-time/ part time	Own malpractice Insurance? Limits

44. Has applicant or any of its staff's license to practice medicine or license to prescribe or Yes No N/A dispense drugs ever been limited, suspended, revoked, placed on probation or been voluntarily surrendered in any province/territory?

If 'Yes', please explain:



45.	5. Are any of the above-listed physicians to be listed under applicant's policy? If 'Yes', please provide CV for each physician		Yes	No	N/A
46.	Do a	any of the physicians have direct patient care responsibilities?	Yes	No	N/A
47.	Prior	r to hiring any employee, do you verify the following:			
	a.	Education background/training?	Yes	No	N/A
	b.	Employment references with at least two previous employers?	Yes	No	N/A
	C.	Criminal record on Local/Provincial/Territorial/National?	Yes	No	N/A
	d.	Driving record?	Yes	No	N/A
	e.	Drug Test?	Yes	No	N/A
48.	Are a	all health professionals credentialed prior to hiring?	Yes	No	N/A
	a.	If 'Yes', how often are physicians re-credentialed?			
49.	Has the applicant or any staff ever been the subject of disciplinary/investigative proceedings or reprimand by a governmental/administrative agency, hospital, or professional association?		Yes	No	N/A
	If 'Yes', please explain:				



Section 6 – Errors and Omissions

50.	Are any contracts past due, customers stopped payments or requested refunds? If 'Yes', please explain:	Yes	No	N/A
51.	Do you have formal written contracts/agreements in place with all clients/customers?	Yes	No	N/A
52.		Yes	No	N/A
53.	Do the contracts include the following provisions: a. all duties and responsibilities of each party	Yes	No	N/A
	b. arbitration clause	Yes	No	N/A
	c. choice of law or jurisdiction	Yes	No	N/A
	d. force Majeure	Yes	No	N/A
	e. guarantees/warranty disclaimers	Yes	No	N/A
	f. hold harmless agreements/indemnification	Yes	No	N/A
	g. limitation of consequential damages	Yes	No	N/A
	h. limitation of liabilities/capping of limits	Yes	No	N/A
54.	Does an attorney review all contracts or agreements including changes prior to use?	Yes	No	N/A
55.	Do you contract out product development, manufacturing, packaging, sales, distribution, sterilization and/or validation?	Yes	No	N/A
56.	Do you receive a hold harmless agreement from each contractor?	Yes	No	N/A
57.	Do you obtain Certificate of Insurance from all manufacturers/suppliers evidencing Product Liability insurance?	Yes	No	N/A
	If so, what are the minimum limits required?	\$		
58.	What is the largest contract by revenue:	\$		
59.	What is the longest contract by duration (month)			
60.	What is the average value and duration of contracts: \$	month		



Section 7 – Regulatory/Risk Management

(NOTE: UW may request to review copies of QC/QA, Product Recall, Contract Agreements as part of the submission)

61.		ne best of your knowledge, are you in compliance with the Health Canada regulation if applicable, the foreign agency equivalent?	s Yes	No	N/A
	a.	Have there been any incidents of non-compliance (including sales and marketing practices)in the past 5 years?	Yes	No	N/A
		If 'Yes', please explain:			
	b.	Do you have a formal Quality Control program?	Yes	No	N/A
	C.	Do you have a formal Loss Control/Risk Management program?	Yes	No	N/A
	d.	Do you have a formal written Product Recall plan?	Yes	No	N/A
	e.	Do you have a Records Retention Plan?	Yes	No	N/A
	f.	Do you require all sales personnel to participate in a formal training program that instructs them on all applicable company policies and procedures?	Yes	No	N/A
	g.	Do you have any products that do not have a formal Health Canada and if applicable foreign agency equivalent approval for marketing?	le, Yes	No	N/A
		If 'Yes', please explain:			
	h.	When was your last Health Canada inspection (if relevant)? (mm,	/dd/yyyy)	/	/
		Were you issued a notice as part of this inspection? If 'Yes', please provide a copy along with your responses, if applicable	Yes	No	N/A
		i. Do you audit foreign/domestic suppliers?	Yes	No	N/A
		If 'Yes', when was the last audit and result:			
	j.	Do your product(s) require a Risk Evaluation & Mitigation Strategy (REMS)? If 'Yes', what product(s):	Yes	No	N/A



Section 8 – Loss Information

62. Please provide details of applicant's total aggregate losses, from the 1st dollar, including expenses (and please also attach hard copy loss runs for the last 5 years): If None, check here

None

	Policy Period	Insurer	Number of Claims	Tot	al Cost In	curred
a.	Any claim(s)/known occurrence(s) not yet reported?				No	N/A
b.	Does the applicant handle claims in-house or utilise the services of a third party administrator?				No	N/A
c.	Has any claim or suit for an error, omission or malpractice ever been made against applicant or any employees/staff working on its behalf?				No	N/A
d.	Any product or service has been/is involved with any certified/attempted class action or multi-national litigation?			Yes	No	N/A
e.	Has your insurance ever been cancelled or non-renewed by a carrier?				No	N/A
	10/ 11					

If answered 'Yes', to any questions 62a - e, please explain below:



Declaration

The undersigned is authorized by the applicant and declares that the statements set forth herein and all written statements and materials furnished to the insurer in conjunction with this application are true. Signing of this application does not bind the applicant or the insurer to complete the insurance, but it is agreed that the statements contained in this application, any supplemental attachments, and the materials submitted herewith are the basis of the contract should a policy be issued and have been relied upon by the insurer in issuing any policy.

This application and materials submitted with it shall be retained on file with the insurer and shall be deemed attached to and become part of the policy if issued. The insurer is authorized to make any investigation and inquiry in connection with this application as it deems necessary.

The applicant agrees that if the information supplied on this application changes between the date of this application and the effective date of the insurance, the applicant will, in order for the information to be accurate on the effective date of the insurance, immediately notify the insurer of such changes, and the insurer may withdraw or modify any outstanding quotations or authorizations or agreements to bind the insurance

I have read the foregoing application of insurance and any attachment and represent that the responses provided on behalf of the applicant are true and correct.

Warning

Any person who, with intent to defraud or knowing that (s)he is facilitating a fraud against the insurer, submits an application or files a claim containing a false or deceptive statement may be guilty of insurance fraud.

Signature:	
Print name:	
Position held (Owner, partner, authorised officer):	Title:
Date: / /	



Insurance Act 2015 – Duty of Fair Presentation

- 1. Before this insurance contract is entered into, the Insured must make a fair presentation of the risk to the Insurer, in accordance with Section 3 of the Insurance Act 2015. In summary, the Insured must:
 - a. Disclose to the Insurer every material circumstance which the Insured knows or ought to know. Failing that, the Insured must give the Insurer sufficient information to put a prudent insurer on notice that it needs to make further enquiries in order to reveal material circumstances. A matter is material if it would influence the judgement of a prudent insurer as to whether to accept the risk, or the terms of the insurance (including premium);
 - b. Make the disclosure in clause (1)(a) above in a reasonably clear and accessible way; and
 - c. Ensure that every material representation of fact is substantially correct, and that every material representation of expectation or belief is made in good faith.
- 2. For the purposes of clause (1.)(a.) above, the Insured is expected to know the following:
 - If the Insured is an individual, what is known to the individual and anybody who is responsible for arranging his
 or her insurance.
 - b. If the Insured is not an individual, what is known to anybody who is part of the Insured's senior management; or anybody who is responsible for arranging the Insured's insurance.
 - c. Whether the Insured is an individual or not, what should reasonably have been revealed by a reasonable search of information available to the Insured. The information may be held within the Insured's organisation, or by any third party (including but not limited to subsidiaries, affiliates, the broker, or any other person who will be covered under the insurance). If the Insured is insuring subsidiaries, affiliates or other parties, the Insurer expects that the Insured will have included them in its enquiries, and that the Insured will inform the Insurer if it has not done so. The reasonable search may be conducted by making enquiries or by any other means.

LMA9117

16 March 2016

